[Secondary osteoporosis UPDATE. Bone disease with decreased kidney function].
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is considered to be a systemic disorder that associated with fracture, cardiovascular disease, and mortality. Because the early initiation of appropriate therapy may prevent or ameliorate the mineral and bone disorder that developed in late CKD, the ability to define the pathophysiologic process underling abnormality is important. In patients with earlier stage of CKD with osteoporosis or high risk of fracture, management similar to the general population is recommended. There are few data on the treatment for fragility fractures in patients with later stage of CKD.
Okuno
Senji
S
Shirasagi Clinic.
Ishimura
Eiji
E
D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D002908:Chronic Disease; D004164:Diphosphonates / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000150:complications* / Q000175:diagnosis; D008903:Minerals / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012015:Reference Standards
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D008903:Minerals; D020849:Raloxifene Hydrochloride